{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T21:00:20.849568+00:00","company":{"ticker":"INKT","cik":1840229,"company_name":"MiNK Therapeutics, Inc."},"pagination":{"limit":100,"returned":5,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"b2ca913d0ebf4bf12c3c494bc0e732891438e871","cik":1840229,"ticker":"INKT","company_name":"MiNK Therapeutics, Inc.","filed_at":"2026-03-31T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss for the quarter ended December 31, 2025, was $2.6 million, or $0.56 per share","period_text":"the fourth quarter and full year ended December 31, 2025","report_date":"2026-03-31","result_type":"reported_results","revenue_text":null},"claim":"MiNK Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income net loss for the quarter ended December 31, 2025, was $2.6 million, or $0.56 per share.","evidence_excerpt":"On March 31, 2026, MiNK Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter and year ended December 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-133346","anchor_url":"https://secwatch.observer/filing/0001193125-26-133346#claim-b2ca913d0ebf4bf12c3c494bc0e732891438e871","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/0001193125-26-133346-index.htm"},{"fact_type":"executive_change","fact_key":"0b8f1cd6db","cik":1840229,"ticker":"INKT","company_name":"MiNK Therapeutics, Inc.","filed_at":"2024-10-31T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Robert Kadlec was elected as Director at MiNK Therapeutics, Inc..","evidence_excerpt":"On October 30, 2024, the Board of Directors (the “Board”) of MiNK Therapeutics Inc., (\"MiNK\") elected Dr. Robert Kadlec to become a Class II director of MiNK with an initial term that expires at MiNK's annual meeting of stockholders in 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-119270","anchor_url":"https://secwatch.observer/filing/0000950170-24-119270#claim-0b8f1cd6db","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840229/000095017024119270/0000950170-24-119270-index.htm"},{"fact_type":"executive_change","fact_key":"89eb605ee0","cik":1840229,"ticker":"INKT","company_name":"MiNK Therapeutics, Inc.","filed_at":"2024-10-18T23:59:59+00:00","payload":{"action":"transitioned from","action_category":"role_change","departure_tone":"routine","effective_date":"2024-11-15","interim":false,"role":"Chief Scientific Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dr. Marc Van Dijk changed role as Chief Scientific Officer at MiNK Therapeutics, Inc..","evidence_excerpt":"Dr. Marc Van Dijk will transition from his role as Chief Scientific Officer and assume the positions of Scientific Advisory Board Member and Strategic Consultant.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-115596","anchor_url":"https://secwatch.observer/filing/0000950170-24-115596#claim-89eb605ee0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840229/000095017024115596/0000950170-24-115596-index.htm"},{"fact_type":"earnings_release","fact_key":"5542d84f80ff8087bda226bc3104e8f056038b7c","cik":1840229,"ticker":"INKT","company_name":"MiNK Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":"$0.11 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$3.8 million, or $0.11 per share","period_text":"for the first quarter 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"MiNK Therapeutics, Inc. reported for the first quarter 2024 results: net income $3.8 million, or $0.11 per share, EPS $0.11 per share.","evidence_excerpt":"Net loss for the first quarter of 2024 was $3.8 million, or $0.11 per share, compared to $5.7 million, or $0.17 per share, for the first quarter of 2023.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001171843-24-002826","anchor_url":"https://secwatch.observer/filing/0001171843-24-002826#claim-5542d84f80ff8087bda226bc3104e8f056038b7c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324002826/0001171843-24-002826-index.htm"},{"fact_type":"earnings_release","fact_key":"a44bbef66df4c213d4ad3ebc01a024750bfc4bad","cik":1840229,"ticker":"INKT","company_name":"MiNK Therapeutics, Inc.","filed_at":"2024-03-21T23:59:59+00:00","payload":{"eps_text":"$0.65","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share","period_text":"fourth quarter and full-year 2023","report_date":"2024-03-21","result_type":"reported_results","revenue_text":null},"claim":"MiNK Therapeutics, Inc. reported fourth quarter and full-year 2023 results: net income Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share, EPS $0.65.","evidence_excerpt":"MiNK Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001171843-24-001514","anchor_url":"https://secwatch.observer/filing/0001171843-24-001514#claim-a44bbef66df4c213d4ad3ebc01a024750bfc4bad","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840229/000117184324001514/0001171843-24-001514-index.htm"}]}